High-Intensity Treadmill Exercise for Parkinson's Disease
(SPARX3 Trial)
Trial Summary
What is the purpose of this trial?
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 months in among persons who have not initiated medication for Parkinson Disease (PD) when they perform high-intensity endurance treadmill exercise.
Will I have to stop taking my current medications?
Yes, if you are currently taking medications for Parkinson's disease, you will need to stop them to participate in this trial. The study excludes anyone who has used Parkinson's medications like levodopa or dopamine agonists in the 60 days before the trial starts.
What data supports the effectiveness of the treatment High-Intensity Treadmill Exercise for Parkinson's Disease?
Is high-intensity treadmill exercise safe for people with Parkinson's disease?
How does high-intensity treadmill exercise differ from other treatments for Parkinson's disease?
High-intensity treadmill exercise is unique because it focuses on improving walking capacity and gait through structured, repetitive walking sessions, which may lead to positive changes in the brain's ability to adapt (neural plasticity). Unlike medications, this treatment directly targets physical symptoms like stride length and speed, and its benefits can persist even after the exercise sessions have ended.1231011
Research Team
Daniel M Corcos, PhD
Principal Investigator
Northwestern University
Eligibility Criteria
This trial is for people aged 40-80 with early-stage Parkinson's disease (diagnosed within the last 3 years and not severe), who haven't started medication. They must have a positive DaTscan, be able to exercise, and not have other serious health issues or recent use of certain medications that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in treadmill exercise 4 times per week at either 60-65% HRmax or 80-85% HRmax
Follow-up
Participants are monitored for changes in motor symptoms, quality of life, and other health metrics
Exploratory
Assessment of the sustainability and durability of exercise effects after removal of study support
Treatment Details
Interventions
- Treadmill walking
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
The Parkinson Study Group
Collaborator
University of Pittsburgh
Collaborator